AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates

What happened: AbbVie ($ABBV) reported quarterly adjusted earnings of $3.82 per share and revenue of $17.4 billion, beating Zacks consensus estimates on both. Key numbers: EPS $3.82 vs. $3.74 estimate, a +2.14% surprise; year-ago EPS $1.86. Revenue $17.4 billion vs. estimate beat of 0.20%; year-ago revenue $15.78 billion. Shares up about 27.3% year to date vs. S&P 500's 12.8%. Zacks Rank #4 (Sell). Why it matters: Estimate revisions trend was unfavorable ahead of the release, translating to a Zacks Rank #4 (Sell), and the shares are expected to underperform the market in the near future. Market: +1.7% today ($290.79), +28.9% YTD, 0.9x vol — as of 13:15 UTC Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29 Coverage: 4 outlets in 24h

AbbVie ($ABBV) reported quarterly adjusted earnings of $3.82 per share and revenue of $17.4 billion, beating Zacks consensus estimates on both.

Estimate revisions trend was unfavorable ahead of the release, translating to a Zacks Rank #4 (Sell), and the shares are expected to underperform the market in the near future. Market: +1.7% today ($290.79), +28.9% YTD, 0.9x vol — as of 13:15 UTC Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29